Cannabis use and attention deficit/hyperactivity disorder: a systematic review
DOI:
https://doi.org/10.18004/anales/2020.053.01.41-048Keywords:
Attention deficit hyperactivity disorder, Cannabis, Children, Adolescents, Adults, ParaguayAbstract
Introduction: Attention deficit hyperactivity disorder is a neurodevelopmental disorder with a prevalence of 5% in children and adolescents and 2.5% in adults and is associated with high comorbidity with cannabis use disorder, other substance use and other psychiatric disorders.Objective: To determine the current scientific evidence on cannabis use and the development of attention deficit hyperactivity disorder. Methodology: This was a systematic review of the literature. An online search of relevant publications was conducted in PubMed, CICCO and Web of Science databases. The search was limited to articles written in English or Spanish, between 2008 and 2019. The search syntax included: “cannabis AND ADHD”, “Attention-deficit/hyperactivity AND cannabis”. Results: 229 related publications were found. Most of the excluded texts corresponded to studies that did not report a causal relationship between cannabis and attention deficit hyperactivity disorder, which was the objective of this systematic review. Those full texts that presented cannabis as a treatment for the disorder or because they reported that people with this diagnosis were more prone to substance use were excluded. Discussion: Cannabis use reduces levels of striatal dopamine synthesis and is associated with deficits of executive function and synergistic reduction of dopamine, causing an exacerbation of the cognitive deficit related to attention deficit disorder or the use of cannabis itself. Also, cannabis use leads to the use of other drugs, which in turn produces an increase in symptoms of attention deficit disorder. The causal relationship of cannabis use and subsequent development of attention deficit hyperactivity disorder should be studied further, since research on this particular aspect is few and inconclusive.
References
1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The Worldwide Prevalence of ADHD: A Systematic Review and Metaregression Analysis. Am J Psychiatry. 2007;164(6):942-948.
2. Simon V, Czobor P, Bálint S, Mészáros A, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry J Ment Sci. 2009;194(3):204-211.
3. Du Rietz E, Kuja-Halkola R, Brikell I, Jangmo A, Sariaslan A, Lichtenstein P, et al. Predictive validity of parent- and self-rated ADHD symptoms in adolescence on adverse socioeconomic and health outcomes. Eur Child Adolesc Psychiatry. 2017;26(7):857-867.
4. Cuffe SP, Visser SN, Holbrook JR, Danielson ML, Geryk LL, Wolraich ML, et al. ADHD and Psychiatric Comorbidity: Functional Outcomes in a School-Based Sample of Children. J Atten Disord. 2015;1087054715613437.
5. Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28(10):1059-1088.
6. Zaman T, Malowney M, Knight J, Boyd JW. Co-Occurrence of Substance-Related and Other Mental Health Disorders Among Adolescent Cannabis Users. J Addict Med. 2015;9(4):317-321.
7. Karila L, Roux P, Rolland B, Benyamina A, Reynaud M, Aubin H-J, et al. Acute and Long-Term Effects of Cannabis Use: A Review. Curr Pharm Des. 2014;20(25):4112-4118.
8. Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006;8(1):37-43.
9. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Cannabis use and cannabis use disorders among individuals with mental illness. Compr Psychiatry. 2013;54(6):589-598.
10. Hayatbakhsh MR, McGee TR, Bor W, Najman JM, Jamrozik K, Mamun AA. Child and adolescent externalizing behavior and cannabis use disorders in early adulthood: an Australian prospective birth cohort study. Addict Behav. 2008;33(3):422-438.
11. Zullino DF, Rathelot T, Khazaal Y. Cannabis and psychosis. Lancet Lond Engl. 2007;370(9598):1540.
12. Torales J, Ventriglio A, Vitrani G, Barrios I, Medina A, Ruiz Díaz C, González I, Arce A. Uso de cannabis y desarrollo de esquizofrenia: ¿cuáles son los vínculos?. An. Fac. Cienc. Méd. (Asunción) 2017;50(2):95-102.
13. Ortiz-Medina MB, Perea M, Torales J, Ventriglio A, Vitrani G, Aguilar L, et al. Cannabis consumption and psychosis or schizophrenia development. Int J Soc Psychiatry 2018;64(7):690-704.
14. Shrivastava A, Johnston M, Terpstra K, Bureau Y. Pathways to psychosis in cannabis abuse. Clin Schizophr Relat Psychoses. 2015;9(1):30-35.
15. Kuepper R, van Os J, Lieb R, Wittchen H-U, Henquet C. Do cannabis and urbanicity co-participate in causing psychosis? Evidence from a 10-year follow-up cohort study. Psychol Med. 2011;41(10):2121-2129.
16. Kuepper R, van Os J, Lieb R, Wittchen H-U, Höfler M, Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ. 2011;342:d738.
17. Large M, Sharma S, Compton MT, Slade T, Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011;68(6):555-561.
18. Reece AS. Chronic toxicology of cannabis. Clin Toxicol Phila Pa. 2009;47(6):517-524.
19. Price C, Hemmingsson T, Lewis G, Zammit S, Allebeck P. Cannabis and suicide: longitudinal study. Br J Psychiatry J Ment Sci. 2009;195(6):492-497.
20. Serafini G, Pompili M, Innamorati M, Rihmer Z, Sher L, Girardi P. Can cannabis increase the suicide risk in psychosis? A critical review. Curr Pharm Des. 2012;18(32):5165-5187.
21. Crippa JA, Zuardi AW, Martín-Santos R, Bhattacharyya S, Atakan Z, McGuire P, et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol. 2009;24(7):515-523.
22. Buckner JD, Schmidt NB, Bobadilla L, Taylor J. Social anxiety and problematic cannabis use: evaluating the moderating role of stress reactivity and perceived coping. Behav Res Ther. 2006;44(7):1007-1015.
23. Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J. Bipolar disorder and co-occurring cannabis use disorders: characteristics, co-morbidities and clinical correlates. Psychiatry Res. 2013;209(3):459-465.
24. Lange KW, Reichl S, Lange KM, Tucha L, Tucha O. The history of attention deficit hyperactivity disorder. ADHD Atten Deficit Hyperact Disord. 2010;2(4):241-255.
25. Heidbreder R. ADHD symptomatology is best conceptualized as a spectrum: a dimensional versus unitary approach to diagnosis. ADHD Atten Deficit Hyperact Disord. 2015;7(4):249-269.
26. Torgersen T, Gjervan B, Rasmussen K. ADHD in adults: A study of clinical characteristics, impairment and comorbidity. Nord J Psychiatry. 2006;60(1):38-43.
27. Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2007;257(7):371-377.
28. Katzman MA, Bilkey T, Chokka PR, Fallu A, Klassen LJ. Re: Is Adult Attention-Deficit Hyperactivity Disorder Being Overdiagnosed? Can J Psychiatry. 2016;61(1):60-61.
29. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do Stimulants Protect Against Psychiatric Disorders in Youth With ADHD? A 10-Year Follow-up Study. PEDIATRICS. 2009;124(1):71-78.
30. Biederman J, Wilens T, Mick E, Spencer T, Faraone SV. Pharmacotherapy of Attention-deficit/Hyperactivity Disorder Reduces Risk for Substance Use Disorder. Pediatrics. 1999;104(2):e20–e20.
31. Loflin M, Earleywine M, De Leo J, Hobkirk A. Subtypes of Attention Deficit-Hyperactivity Disorder (ADHD) and Cannabis Use. Subst Use Misuse. 2014;49(4):427-434.
32. Wallace AL, Wade NE, Hatcher KF, Lisdahl KM. Effects of Cannabis Use and Subclinical ADHD Symptomology on Attention Based Tasks in Adolescents and Young Adults. Arch Clin Neuropsychol. 2018;34(5):700-705.
33. Lamy S, Laqueille X, Thibaut F. Conséquences potentielles de la consommation de tabac, de cannabis et de cocaïne par la femme enceinte sur la grossesse, le nouveau-né et l’enfant: revue de littérature. L’Encéphale. 2015;41:S13-20.
34. Notzon DP, Pavlicova M, Glass A, Mariani JJ, Mahony AL, Brooks DJ, et al. ADHD Is Highly Prevalent in Patients Seeking Treatment for Cannabis Use Disorders. J Atten Disord. 2016;10.1177/1087054716640109
35. Murray RM, Quigley H, Quattrone D, Englund A, Forti MD. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195-204.
36. Fergusson DM, Boden JM. Cannabis use and adult ADHD symptoms. Drug Alcohol Depend. 2008;95(1):90-96.
37. Kolla NJ, van der Maas M, Toplak ME, Erickson PG, Mann RE, Seeley J, et al. Adult attention deficit hyperactivity disorder symptom profiles and concurrent problems with alcohol and cannabis: sex differences in a representative, population survey. BMC Psychiatry. 2016;16(1):50.
38. Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7–8):579-589.
39. Rasmussen J, Casey BJ, van Erp TGM, Tamm L, Epstein JN, Buss C, et al. ADHD and Cannabis Use in Young Adults Examined Using fMRI of a Go/NoGo Task. Brain Imaging Behav. 2016;10(3):761-771.
40. Kelly C, Castellanos FX, Tomaselli O, Lisdahl K, Tamm L, Jernigan T, et al. Distinct effects of childhood ADHD and cannabis use on brain functional architecture in young adults. NeuroImage Clin. 2017;13:188-200.
